Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Obesity or Overweight Without Type 2 Diabetes
NCT06972459Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of orforglipron in obesity, sponsored by Eli Lilly and Company. Started May 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06972459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972459.